Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
The Laurus Labs analyst fair value estimate has shifted from ₹1,044.00 to about ₹1,486.29, which is a sizeable uplift in the latest price target. This revision reflects how some analysts now see the stock, with more optimistic views on valuation sitting alongside others that remain cautious about growth durability and execution risk. As you read on, you will see how these differing opinions shape the evolving Laurus Labs story and what to watch in the next phase of the narrative.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Barrington highlights what it sees as attractive valuation for the stock, pointing to Laurus Labs as trading at a discount to its peer group in its sector.
-
The firm also points to supportive demand and operational trends in key markets as reasons it views Laurus Labs as undervalued on its stated price target framework.
🐻 Bearish Takeaways
-
Some analysts express concern that recent gains in Laurus Labs already reflect much of the anticipated growth and cash generation, which leads to more neutral stances on the valuation.
-
Others flag the risk that current consensus expectations may be too optimistic if future efficiency gains slow, which could affect how comfortably Laurus Labs meets growth and profitability assumptions embedded in forecasts.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 1 risk for Laurus Labs. See which could impact your investment.
How This Changes the Fair Value For Laurus Labs
-
Fair value for Laurus Labs has moved from ₹1,044.00 to about ₹1,486.29.
-
Revenue growth assumption in the forecasts has shifted from 14.63% to about 17.00%.
-
Net profit margin assumption has changed from 15.40% to about 18.30%.
-
Future P/E assumption has moved from about 50.81x to about 53.45x.
-
Discount rate has adjusted from 12.514% to 12.436%.
Never Miss an Update: Follow The Narrative
Narratives connect Laurus Labs' business story to the analyst forecasts and fair value assumptions behind the numbers. They update as new information comes through so you can see how the investment case is evolving in real time.
Head over to the Simply Wall St Community and follow the Narrative on Laurus Labs to stay up to date on:
-
How Laurus Labs is building out high margin CDMO, biologics and gene therapy projects off a large planned CapEx program.
-
The shift away from ARV APIs toward non ARV therapies, animal health, agrochemicals and other diversified revenue streams.
-
Key pressure points including high ongoing capital needs, rising net debt, regulatory scrutiny and global generic drug price compression.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LAURUSLABS.nsei .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
